Head-to-head · WeighScore
altRX vs Eden
By GLP-1 ScorecardUpdated
Score comparison
Eden has the higher recorded score — 81.6/100 to 66/100.
Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.
Before you choose
Before comparing the headline prices, the altRX review and the Eden review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, altRX vs Effecty and AM Rx vs Eden compare each of them with another graded program, and the list of alternatives to altRX ranks the programs closest to altRX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | altRX | Eden |
|---|---|---|
| WeighScore | 66/100 | 81.6/100 |
| Grade | C | B− |
| Site position | #223 | #16 |
| Semaglutide | $89/mo (advertised, compounded; selected term and charge unverified) | Advertised $99/mo bundle; linked membership terms conflict—confirm checkout |
| Tirzepatide | $149/mo (advertised, compounded; selected term and charge unverified) | Advertised $129/mo bundle; linked membership terms conflict—confirm checkout |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
FDAWarning letter issued to Trinity HealthCare Supply, LLC dba altRx in June 2026. See the FDA warning-letter database.
Strengths
- Publishes separate compounded treatment pages
- Lists Zepbound, Wegovy and Ozempic on the public menu
- Publishes a cancellation cutoff
What to consider
- The displayed rates do not establish the selected charge
- Bundled plans are generally nonrefundable
- Cancellation requires at least 72 hours’ notice before renewal
Site position #16 · B−
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Strengths
- Current compounded offer includes medication and support
- Homepage also advertises branded prescription pathways; eligibility and cost require confirmation
- Named pharmacy operation and partner network can be investigated
What to consider
- Linked membership terms describe a separate fee model
- Landing-page warranty and terms use different thresholds and conditions
- FDA warning history remains relevant; a new offer does not establish resolution
Featured provider
Eden
Eden scores 81.6/100 (B−). Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.